Microneedle Patch for Fast Onset and Long-Lasting Delivery of Painkillers

  • Jaspreet Singh Kochhar
  • Justin J. Y. Tan
  • Yee Chin Kwang
  • Lifeng Kang


Chronic pain afflicts many worldwide. Topical lidocaine has been known for its analgesic properties apart from its known role as a local anaesthetic in the management of both acute and chronic pain. Despite its widespread use, major concerns relating to its lack of efficacy arising from poor skin permeability persists. In this chapter, we explore the use of ultraviolet curing to fabricate a microneedle integrated transdermal patch (MITP) encapsulating lidocaine, allowing higher loading of the drug than previously reported methods. This integrated patch system is intended to provide a reservoir system with high drug loading, delivering the initial drug load rapidly and following that, a sustained release of the active ingredient. Therefore, this integrated patch could serve as an excellent drug delivery tool for paediatric applications and chronic care management, as well as in home care settings due to its ease of application.


Chronic pain Painkiller Lidocaine Microneedle integrated transdermal patch 


  1. 1.
    Koneti KK et al (2013) Management of acute pain. Surgery (UK) 31:77–83Google Scholar
  2. 2.
    Anonymous (2010) Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology 112:810–833CrossRefGoogle Scholar
  3. 3.
    Reimer-Kent J (2004) Improving post-operative pain management by focusing on prevention. Nurs BC 36:20–24PubMedGoogle Scholar
  4. 4.
    T.A.A.o. P Medicine (2013) AAPM facts and figures on pain. Retrieved May 25, 2019, from
  5. 5.
    Breivik H et al (2006) Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 10:287–333CrossRefGoogle Scholar
  6. 6.
    Global Industry Analysts I (2011) Retrieved April 29, 2013, from
  7. 7.
    Evans SR et al (2011) Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 25:919–928CrossRefGoogle Scholar
  8. 8.
    Herberger K et al (2012) Local anesthetic effects of Lidocaine cream: randomized controlled trial using a standardized prick pain. J Dermatolog Treat 23:437–442CrossRefGoogle Scholar
  9. 9.
    Mick G et al (2012) Topical pain management with the 5% lidocaine medicated plaster—a review. Curr Med Res Opin 28:937–951CrossRefGoogle Scholar
  10. 10.
    Meier T et al (2003) Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 106:151–158CrossRefGoogle Scholar
  11. 11.
    Galer BS et al (1999) Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 80:533–538CrossRefGoogle Scholar
  12. 12.
    AstraZeneca (2013) emla® dermal anaesthetic. Retrieved April 29, 2013, from
  13. 13.
    Comer AM et al (2000) Lidocaine patch 5%. Drugs 59:245–249. discussion 250-241CrossRefGoogle Scholar
  14. 14.
    Rowbotham MC et al (1996) Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 65:39–44CrossRefGoogle Scholar
  15. 15.
    Fleming JA et al (2009) Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res Manag 14:381–388CrossRefGoogle Scholar
  16. 16.
    Wermeling DP et al (2008) Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc Natl Acad Sci U S A 105:2058–2063CrossRefGoogle Scholar
  17. 17.
    Gupta J et al (2012) Rapid local anesthesia in humans using minimally invasive microneedles. Clin J Pain 28:129–135CrossRefGoogle Scholar
  18. 18.
    Gupta J et al (2011) Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabetes Technol Ther 13:451–456CrossRefGoogle Scholar
  19. 19.
    Zhang Y et al (2012) Development of lidocaine-coated microneedle product for rapid, safe, and prolonged local analgesic action. Pharm Res 29:170–177CrossRefGoogle Scholar
  20. 20.
    Lee JW et al (2008) Dissolving microneedles for transdermal drug delivery. Biomaterials 29:2113–2124CrossRefGoogle Scholar
  21. 21.
    Ito Y et al (2013) Method to increase the systemically delivered amount of drug from dissolving microneedles. Chem Pharm Bull (Tokyo) 61:8–15CrossRefGoogle Scholar
  22. 22.
    Kochhar JS et al (2013) A simple method of microneedle array fabrication for transdermal drug delivery. Drug Dev Ind Pharm 39:299–309CrossRefGoogle Scholar
  23. 23.
    Cui Y et al (2006) Characterization of supersaturated lidocaine/polyacrylate pressure sensitive adhesive systems: thermal analysis and FT-IR. J Pharm Sci 95:701–713CrossRefGoogle Scholar
  24. 24.
    Kaihara S et al (2008) Synthesis and characterization of cyclic acetal based degradable hydrogels. Eur J Pharm Biopharm 68:67–73CrossRefGoogle Scholar
  25. 25.
    Kim YC et al (2012) Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 64:1547–1568CrossRefGoogle Scholar
  26. 26.
    Baker S (2011) Pain-management market projected to grow to $60 Billion. Pharmaceutical and Medical Packaging NewsGoogle Scholar
  27. 27.
    Kochhar JS et al (2012) Protein encapsulation in polymeric microneedles by photolithography. Int J Nanomedicine 7:3143–3154PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Jaspreet Singh Kochhar
    • 1
  • Justin J. Y. Tan
    • 2
  • Yee Chin Kwang
    • 3
  • Lifeng Kang
    • 3
  1. 1.Procter & GambleSingaporeSingapore
  2. 2.Department of PharmacyNational University of SingaporeSingaporeSingapore
  3. 3.School of PharmacyUniversity of SydneySydneyAustralia

Personalised recommendations